Skip to main content

. 1987 May 23;294(6583):1323–1324. doi: 10.1136/bmj.294.6583.1323-a

Clinical evaluation of lysuride in the management of hyperprolactinaemia.

P M Bouloux, G M Besser, A Grossman, P J Moult

PMCID: PMC1246488 PMID: 3109638

1323

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Casson I. F., Walker B. A., Hipkin L. J., Belchetz P. E. Intolerance of bromocriptine: is metergoline a satisfactory alternative? Br Med J (Clin Res Ed) 1985 Jun 15;290(6484):1783–1784. doi: 10.1136/bmj.290.6484.1783. [DOI] [PMC free article] [PubMed] [Google Scholar]
Chiodini P., Liuzzi A., Cozzi R., Verde G., Oppizzi G., Dallabonzana D., Spelta B., Silvestrini F., Borghi G., Luccarelli G. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J Clin Endocrinol Metab. 1981 Oct;53(4):737–743. doi: 10.1210/jcem-53-4-737. [DOI] [PubMed] [Google Scholar]
Grossman A., Bouloux P. M., Loneragan R., Rees L. H., Wass J. A., Besser G. M. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia. Clin Endocrinol (Oxf) 1985 May;22(5):611–616. doi: 10.1111/j.1365-2265.1985.tb02996.x. [DOI] [PubMed] [Google Scholar]
Gräf K. J., Köhler D., Horowski R., Dorow R. Rapid regression of macroprolactinomas by the new dopamine partial agonist terguride. Acta Endocrinol (Copenh) 1986 Apr;111(4):460–466. doi: 10.1530/acta.0.1110460. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES